Knockdown of EIF3d Inhibits Cell Proliferation Through G2/M Phase Arrest in Non-small Cell Lung Cancer

Overview

Journal Med Oncol

Publisher Springer

Specialty Oncology

Date 2015 May 27

PMID 26008152

Citations 13

Authors

Zhifeng Lin

Liwen Xiong

Qiang Lin

Affiliations

Soon will be listed here.

Abstract

Non-small cell lung cancer (NSCLC) is the most common type of lung cancer and remains the leading cause of cancer-related death worldwide. Eukaryotic translation initiation factor 3, subunit d (eIF3d) has been recognized recently in several human cancers. In this paper, we attempt to evaluate the functional role of eIF3d in NSCLC cells. Lentivirus-mediated RNA interference (RNAi) was applied to silence eIF3d in the human NSCLC cell lines A549 and 95D. Cell viability was measured by MTT. Cell colony-forming ability was measured by colony formation. Cell cycle progression was determined by propidium iodide staining and flow cytometry. Intracellular signaling molecules were detected using a PathScan(®) intracellular signaling array kit. In this study, we firstly proved that lentivirus-mediated RNAi specifically suppressed the expression of eIF3d both at the mRNA and protein levels in A549 and 95D cell lines. Further investigations revealed that eIF3d knockdown significantly inhibited cell proliferation and colony formation. Moreover, the cell cycle of A549 cells was arrested at G2/M phase after eIF3d knockdown. Furthermore, the activations of AKT, HSP27 and SAPK/JNK were suppressed by eIF3d knockdown. This study highlights the crucial role of eIF3d in promoting NSCLC cell proliferation, and provides a foundation for further study into the clinical potential of lentiviral-mediated delivery of eIF3d RNAi therapy for treatment of NSCLC.

Citing Articles

EIF3B stabilizes PCNA by counteracting SYVN1-mediated ubiquitination to serve as a promotor in cholangiocarcinoma.

Huang R, Nie W, Mi L, Yao C, Zhu H Aging (Albany NY). 2024; 16(8):7311-7330.

PMID: 38687509 PMC: 11087095. DOI: 10.18632/aging.205759.

Implications of m6A methylation and microbiota interaction in non-small cell lung cancer: From basics to therapeutics.

Qiu F, He J, Zhong Y, Guo M, Yu C Front Cell Infect Microbiol. 2022; 12:972655.

PMID: 36118041 PMC: 9478539. DOI: 10.3389/fcimb.2022.972655.

Identification of Hub Genes for Early Diagnosis and Predicting Prognosis in Colon Adenocarcinoma.

Xu S, Liu D, Cui M, Zhang Y, Zhang Y, Guo S Biomed Res Int. 2022; 2022:1893351.

PMID: 35774271 PMC: 9239823. DOI: 10.1155/2022/1893351.

Overexpression of Eukaryotic translation initiation factor 3D induces stem cell-like properties and metastasis in cervix cancer by activating FAK through inhibiting degradation of GRP78.

Zhong Y, Lan J Bioengineered. 2022; 13(1):1952-1961.

PMID: 35104170 PMC: 8806159. DOI: 10.1080/21655979.2021.2024336.

Overexpression of in Lung Adenocarcinoma Is a New Independent Prognostic Marker of Poor Survival.

Wang D, Jia Y, Zheng W, Li C, Cui W Dis Markers. 2019; 2019:6019637.

PMID: 31885740 PMC: 6925810. DOI: 10.1155/2019/6019637.

References

Pincheira R, Chen Q, Zhang J . Identification of a 170-kDa protein over-expressed in lung cancers. Br J Cancer. 2001; 84(11):1520-7. PMC: 2363652. DOI: 10.1054/bjoc.2001.1828. View

Dong Z, Liu L, Han B, Pincheira R, Zhang J . Role of eIF3 p170 in controlling synthesis of ribonucleotide reductase M2 and cell growth. Oncogene. 2004; 23(21):3790-801. DOI: 10.1038/sj.onc.1207465. View

Wang Z, Chen J, Sun J, Cui Z, Wu H . RNA interference-mediated silencing of eukaryotic translation initiation factor 3, subunit B (EIF3B) gene expression inhibits proliferation of colon cancer cells. World J Surg Oncol. 2012; 10:119. PMC: 3443437. DOI: 10.1186/1477-7819-10-119. View

Li T, Kung H, Mack P, Gandara D . Genotyping and genomic profiling of non-small-cell lung cancer: implications for current and future therapies. J Clin Oncol. 2013; 31(8):1039-49. PMC: 3589700. DOI: 10.1200/JCO.2012.45.3753. View

Bachmann F, Banziger R, Burger M . Cloning of a novel protein overexpressed in human mammary carcinoma. Cancer Res. 1997; 57(5):988-94. View

Otero J, Suo J, Gordon C, Chang E . Int6 and Moe1 interact with Cdc48 to regulate ERAD and proper chromosome segregation. Cell Cycle. 2009; 9(1):147-61. PMC: 2813716. DOI: 10.4161/cc.9.1.10312. View

Satomi Y . Fucoxanthin induces GADD45A expression and G1 arrest with SAPK/JNK activation in LNCap human prostate cancer cells. Anticancer Res. 2012; 32(3):807-13. View

Jackson R, Hellen C, Pestova T . The mechanism of eukaryotic translation initiation and principles of its regulation. Nat Rev Mol Cell Biol. 2010; 11(2):113-27. PMC: 4461372. DOI: 10.1038/nrm2838. View

Sudo H, Tsuji A, Sugyo A, Kohda M, Sogawa C, Yoshida C . Knockdown of COPA, identified by loss-of-function screen, induces apoptosis and suppresses tumor growth in mesothelioma mouse model. Genomics. 2010; 95(4):210-6. DOI: 10.1016/j.ygeno.2010.02.002. View

10.

Kostenko S, Moens U . Heat shock protein 27 phosphorylation: kinases, phosphatases, functions and pathology. Cell Mol Life Sci. 2009; 66(20):3289-307. PMC: 11115724. DOI: 10.1007/s00018-009-0086-3. View

11.

Kim H, Choi I, Kim C, Kim H, Oshima A, Michalowski A . A gene expression signature of acquired chemoresistance to cisplatin and fluorouracil combination chemotherapy in gastric cancer patients. PLoS One. 2011; 6(2):e16694. PMC: 3041770. DOI: 10.1371/journal.pone.0016694. View

12.

Li H, Zhou F, Wang H, Lin D, Chen G, Zuo X . Knockdown of EIF3D suppresses proliferation of human melanoma cells through G2/M phase arrest. Biotechnol Appl Biochem. 2014; 62(5):615-20. DOI: 10.1002/bab.1305. View

13.

Chang L, Karin M . Mammalian MAP kinase signalling cascades. Nature. 2001; 410(6824):37-40. DOI: 10.1038/35065000. View

14.

Yang X, Qiao D, Meyer K, Friedl A . Signal transducers and activators of transcription mediate fibroblast growth factor-induced vascular endothelial morphogenesis. Cancer Res. 2009; 69(4):1668-77. PMC: 2650265. DOI: 10.1158/0008-5472.CAN-07-6385. View

15.

Fang S, Wang Z . EGFR mutations as a prognostic and predictive marker in non-small-cell lung cancer. Drug Des Devel Ther. 2014; 8:1595-611. PMC: 4189714. DOI: 10.2147/DDDT.S69690. View

16.

Spilka R, Ernst C, Mehta A, Haybaeck J . Eukaryotic translation initiation factors in cancer development and progression. Cancer Lett. 2013; 340(1):9-21. DOI: 10.1016/j.canlet.2013.06.019. View

17.

Haybaeck J, OConnor T, Spilka R, Spizzo G, Ensinger C, Mikuz G . Overexpression of p150, a part of the large subunit of the eukaryotic translation initiation factor 3, in colon cancer. Anticancer Res. 2010; 30(4):1047-55. View

18.

Chen G, Burger M . p150 overexpression in gastric carcinoma: the association with p53, apoptosis and cell proliferation. Int J Cancer. 2004; 112(3):393-8. DOI: 10.1002/ijc.20443. View

19.

van Zandwijk N, Giaccone G . Treatment of metastatic non-small cell lung cancer. Curr Opin Oncol. 1996; 8(2):120-5. DOI: 10.1097/00001622-199603000-00008. View

20.

Wu M, Zhao J, Song S, Zhuo M, Wang X, Bai H . EGFR mutations are associated with prognosis but not with the response to front-line chemotherapy in the Chinese patients with advanced non-small cell lung cancer. Lung Cancer. 2009; 67(3):343-7. DOI: 10.1016/j.lungcan.2009.04.011. View